Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $186,795.00 in Stock

Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $10.50, for a total transaction of $186,795.00. Following the completion of the sale, the insider now directly owns 2,373,387 shares in the company, valued at $24,920,563.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Tuesday, August 8th, Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $207,931.50.
  • On Friday, July 28th, Hbm Healthcare Investments (Ca sold 6,585 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total transaction of $69,208.35.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $1,680.00.
  • On Thursday, July 20th, Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $464,425.50.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total transaction of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.53, for a total transaction of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.52, for a total transaction of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total transaction of $93,795.68.

Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 6.86% during trading on Wednesday, hitting $9.78. 16,009 shares of the stock were exchanged. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $12.75. The stock’s 50 day moving average price is $10.31 and its 200 day moving average price is $10.27. The stock’s market cap is $26.61 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. Analysts forecast that Nabriva Therapeutics AG will post ($2.43) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $186,795.00 in Stock” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/08/09/nabriva-therapeutics-ag-nbrv-major-shareholder-sells-186795-00-in-stock.html.

A number of research firms recently weighed in on NBRV. Cantor Fitzgerald reissued an “overweight” rating on shares of Nabriva Therapeutics AG in a research report on Friday, June 23rd. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. Zacks Investment Research lowered shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Nabriva Therapeutics AG currently has an average rating of “Buy” and a consensus target price of $15.43.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of Nabriva Therapeutics AG during the fourth quarter worth $103,000. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth $1,870,000. Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth $2,074,000. Finally, Wellington Management Group LLP boosted its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares in the last quarter. Hedge funds and other institutional investors own 56.65% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply